Corporate overview

Paris, the son of Priamos, ruler of Troy kidnapped helen from Sparta, the most beautiful woman in the world, and took her to Troy, Menelaos, helen's husband, begged his brother, Agamemnon the most powerful king of Greece at the time to take revenge. They assembled an army and sailed off to Troy. Unable to enter otherwise, they build a Trojan Horse to gain access to the city. It worked, they destroyed Troy and saved Helen.

Since then, the Trojan Horse has been the symbol of unsuspected entry.

Our technology is based on killing agents achieving unsuspected cellular entry using cell translocating peptides (trojan horses), hence the company's name.

Trojantec Ltd ("Trojantec" or the 'Company") a London, UK and Cyprus-based, biopharmaceutical company owns a proprietary platform that offers a completely unique transport mechanism enabling the delivery of a therapy into the cell and/or the subcellular compartments including the nucleus, as well as enabling transport across the blood-brain barrier. Based on its proprietary platform technology the Company has established itself as a World leader in developing first-in-class and best-in-class therapeutic agents that selectively kill both cancer cells and cancer stem cells ("CSC"). Trojantec.

Trojantec has prioritized the advancement of its own cancer therapy programs based on the optimization of this platform delivery technology, with positive results in animal models demonstrating the key features of this novel approach. The lead drug program, TR4, is a first in class biopharmaceutical pursuing a major unmet clinical need of eliminating cancer stem cells and thus preventing recurrence and metastasis.

The delivery system represents a novel platform technology that can be used to deliver an active therapeutic agent into any and all cellular compartments in the body, therefore opening the possibility of addressing a wide range of pathologies.

Trojantec can address disease targets that other companies cannot reach.